These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 31295531)

  • 1. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
    J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoproterenol Disrupts Intestinal Barriers Activating Gut-Liver-Axis: Effects on Intestinal Mucus and Vascular Barrier as Entry Sites.
    Sorribas M; de Gottardi A; Moghadamrad S; Hassan M; Spadoni I; Rescigno M; Wiest R
    Digestion; 2020; 101(6):717-729. PubMed ID: 31550710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.
    Verbeke L; Farre R; Verbinnen B; Covens K; Vanuytsel T; Verhaegen J; Komuta M; Roskams T; Chatterjee S; Annaert P; Vander Elst I; Windmolders P; Trebicka J; Nevens F; Laleman W
    Am J Pathol; 2015 Feb; 185(2):409-19. PubMed ID: 25592258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence.
    Simbrunner B; Hofer BS; Schwabl P; Zinober K; Petrenko O; Fuchs C; Semmler G; Marculescu R; Mandorfer M; Datz C; Trauner M; Reiberger T
    Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
    Schwabl P; Payer BA; Grahovac J; Klein S; Horvatits T; Mitterhauser M; Stift J; Boucher Y; Trebicka J; Trauner M; Angermayr B; Fuhrmann V; Reiberger T; Peck-Radosavljevic M
    J Hepatol; 2014 Jun; 60(6):1135-42. PubMed ID: 24530596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats.
    Lorenzo-Zúñiga V; Rodríguez-Ortigosa CM; Bartolí R; Martínez-Chantar ML; Martínez-Peralta L; Pardo A; Ojanguren I; Quiroga J; Planas R; Prieto J
    Gut; 2006 Sep; 55(9):1306-12. PubMed ID: 16434425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial Translocation Is Linked to Increased Intestinal IFN-γ, IL-4, IL-17, and mucin-2 in Cholestatic Rats.
    Vega-Magaña N; Delgado-Rizo V; García-Benavides L; Del Toro-Arreola S; Segura-Ortega J; Morales ASMZ; Zepeda-Nuño JS; Escarra-Senmarti M; Gutiérrez-Franco J; Haramati J; Bueno-Topete MR
    Ann Hepatol; 2018 Mar; 17(2):318-329. PubMed ID: 29469038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats.
    Chiva M; Guarner C; Peralta C; Llovet T; Gómez G; Soriano G; Balanzó J
    Eur J Gastroenterol Hepatol; 2003 Feb; 15(2):145-50. PubMed ID: 12560758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
    Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
    Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ablation of liver
    Ijssennagger N; van Rooijen KS; Magnúsdóttir S; Ramos Pittol JM; Willemsen ECL; de Zoete MR; Baars MJD; Stege PB; Colliva C; Pellicciari R; Youssef SA; de Bruin A; Vercoulen Y; Kuipers F; van Mil SWC
    JHEP Rep; 2021 Oct; 3(5):100344. PubMed ID: 34604725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
    Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
    Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of interleukin 10 in norfloxacin prevention of luminal free endotoxin translocation in mice with cirrhosis.
    Gómez-Hurtado I; Moratalla A; Moya-Pérez Á; Peiró G; Zapater P; González-Navajas JM; Giménez P; Such J; Sanz Y; Francés R
    J Hepatol; 2014 Oct; 61(4):799-808. PubMed ID: 24882049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
    Fortea JI; Zipprich A; Fernandez-Mena C; Puerto M; Bosoi CR; Almagro J; Hollenbach M; Bañares J; Rodríguez-Sánchez B; Cercenado E; Clément MA; Rose CF; Bañares R; Vaquero J; Ripoll C
    Liver Int; 2018 Jan; 38(1):102-112. PubMed ID: 28665498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
    Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
    Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile Acids and Portal Hypertension.
    Arab JP; Barrera F; Arrese M
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s83-s86. PubMed ID: 29080345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.